Cardiovascular Therapeutics Market size to grow by USD 37.77 billion from 2022 to 2027, The rising prevalence of hypercholesterolemia to drive market growth - Technavio

NEW YORK, April 27, 2023 /PRNewswire/ -- The cardiovascular therapeutics market size is forecast to increase by USD 37.77 billion from 2022 to 2027. The market is estimated to progress at a CAGR of 7.32%, according to the recent market study by Technavio. The growth of the market will be driven by the increasing risk factors for cardiovascular diseases, the availability of advanced diagnostic methods, and the rising prevalence of hypercholesterolemia. Download a Sample Report!

Cardiovascular therapeutics market Vendor Analysis:

The global cardiovascular therapeutics market includes several large and small players that offer branded and generic cardiovascular therapeutics to cater to the growing demand from patients with cardiovascular diseases. Due to the expiry of patents of major drugs in the past few years, generic players are playing a significant role in the market, intensifying the competition among vendors. 

Technavio has extensively analyzed 15 major vendors, including Abbott Laboratories, Acutus Medical Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc.

Get a holistic overview of the cardiovascular therapeutics market by industry experts to
evaluate and develop growth strategies. Download the Sample

Vendor Offerings -

• Abbott Laboratories - The company offers cardiac resynchronization therapy and clinical treatment for patients who deal with heart failure.
• Astellas Pharma Inc. - The company offers lexiscan injection prescription medicine that goes into blood by an intravenous line to increase blood flow through the arteries of the heart during cardiac nuclear stress test.
• AstraZeneca Plc - The company offers ACE inhibitors which are designed to prevent the body from forming angiotensin, thus helping to widen blood vessels and reduce blood pressure to prevent heart attack.

Charts & data tables about market and segment sizes for a historic period (2017-2021)
and forecast period (2023-2027) have been covered in this report. Download The Sample
Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand business operations in the future - To get requisite details, ask for a custom
report.

Cardiovascular therapeutics market - Market Segmentation:

This cardiovascular therapeutics market report extensively covers market segmentation by type (antithrombotic drugs, hypolipidemic drugs, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and geography (Asia, North America, Europe, and Rest of World).

• The market share growth by the antithrombotic drugs segment will be significant during the forecast period. These medications being used more frequently to treat various cardiovascular diseases expands the market. A biological phenomenon called thrombogenesis denotes the development of a blood clot, which involves the two processes of coagulation and platelet aggregation. This results in these medications to further divide into two groups anticoagulants and antiplatelet medications. For instance, the most frequently prescribed antiplatelet medication for the treatment of ischemic stroke and myocardial infarction is aspirin. Hence, such developments are anticipated to grow the segment share during the forecast period.

Cardiovascular therapeutics market - Market Dynamics:

Key DRIVERS:

• The rising prevalence of hypercholesterolemia significantly drives market growth.
• The prevalence of hypercholesterolemia, which is a modifiable risk factor for cardiovascular disease, raises the risk of developing cardiovascular diseases with an atherosclerotic origin. 
• A serious medical condition called atherosclerosis affects the arteries that carry blood to the heart, and the presence of plaque within the artery wall or vessel wall is the primary cause of coronary artery disease.
• Hence, factors like the increased incidence of atherosclerosis caused by the rising prevalence of hypercholesterolemia are anticipated to benefit the global market for cardiovascular therapeutics during the forecast period.

Major Trends:

• A strong incidence of coronary heart disease (CHD) is an emerging trend in the market that is anticipated to fuel market growth.
• The growing number of heart attacks is anticipated to boost demand for cardiovascular therapeutics, which will benefit the global market. 
• The demand for cardiovascular therapeutics also rises due to the prevalence of comorbid conditions, sleep, cognition, and physical imbalance among the elderly population. 
• Maintaining physical and functional ability in older adults is challenging. This is where cardiovascular therapeutic products become important. 
• Moreover, in the US, adults aged 45 years and above experienced a 10.9% incidence rate of CHD in 2019, according to the CDC. 
• Hence, such factors drive the growth of the cardiovascular therapeutics market during the forecast period.

What's New? 

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession  
• Global competitiveness and key competitor positions  
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial - buy the report! 

Key Challenges:

• The side effects associated with cardiovascular therapeutics are a major challenge for the growth of the cardiovascular therapeutics market during the forecast period.
• Small molecules like calcium channel blockers, ACE inhibitors, beta-blockers, antiplatelet agents, nitrates, and statins, which lower cholesterol, dominate the global market.
• Among all of these, statins are the main treatment for cardiovascular conditions with an atherosclerotic etiology. It can have potential side effects despite being therapeutically effective. 
• For instance, ZOCOR (simvastatin), a medication used to lower cholesterol, is categorized as a statin and is used as a supplement to diets and exercises. It reduces the blood level of LDL cholesterol.
• Hence, such challenges hamper the growth of the market during the forecast period.

To get detailed insights about various other market challeneges, buy the report  

What are the key data covered in this Cardiovascular Therapeutics Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the cardiovascular therapeutics market between 2023 and 2027
• Precise estimation of the size of the cardiovascular therapeutics market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the cardiovascular therapeutics market across Asia, North America, Europe, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of the cardiovascular therapeutics market vendors

17,000+ market research reports and market intelligence : Gain instant access withing
MINUTES. 
Technavio's SUBSCRIPTION platform

Related Reports:

The global diagnostic electrocardiograph (ECG) market size is estimated to grow by USD 4.5 billion between 2021 to 2026 accelerating at a CAGR of 8.93%. This diagnostic electrocardiograph (ECG) market report extensively covers market segmentation by End-user (hospitals clinics and cardiac care centers, ambulatory surgical centers, and home setting) and Geography (North America, Europe, Asia, and Rest of World (ROW)). The prevalence of hypertension is increasing globally, leading to a higher risk of heart disease and stroke. 

The cardiovascular catheters market size is estimated to grow at a CAGR of 7.97% between 2022 and 2027. The cardiovascular catheters market size is forecast to increase by USD 6.97 billion. This market report extensively covers market segmentation by product (cardiovascular therapeutic catheters and cardiovascular diagnostic catheters), end-user (hospitals, ambulatory surgical centers, and clinics), and geography (Asia, North America, Europe, and Rest of World (ROW)). The rising incidence of cardiac diseases and the growth of insurance providers are notably driving the market growth.

Browse for Technavio's Health Care Market Reports

Table of Contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global cardiovascular therapeutics market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global cardiovascular therapeutics market 2017 - 2021 ($ billion)

• 4.2 Type Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ billion)

• 4.3 Distribution channel Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ billion)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

• 6.1 Market segments
• Exhibit 30: Chart on Type - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Type - Market share 2022-2027 (%)

• 6.2 Comparison by Type
• Exhibit 32: Chart on Comparison by Type
• Exhibit 33: Data Table on Comparison by Type

• 6.3 Antithrombotic drugs - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Antithrombotic drugs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 35: Data Table on Antithrombotic drugs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 36: Chart on Antithrombotic drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Antithrombotic drugs - Year-over-year growth 2022-2027 (%)

• 6.4 Hypolipidemic drugs - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Hypolipidemic drugs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 39: Data Table on Hypolipidemic drugs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 40: Chart on Hypolipidemic drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Hypolipidemic drugs - Year-over-year growth 2022-2027 (%)

• 6.5 Others - Market size and forecast 2022-2027 
• Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 6.6 Market opportunity by Type 
• Exhibit 46: Market opportunity by Type ($ billion)
• Exhibit 47: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 48: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel 
• Exhibit 50: Chart on Comparison by Distribution Channel
• Exhibit 51: Data Table on Comparison by Distribution Channel

• 7.3 Hospital pharmacy - Market size and forecast 2022-2027 
• Exhibit 52: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 53: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 54: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)

• 7.4 Retail pharmacy - Market size and forecast 2022-2027 
• Exhibit 56: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 57: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 58: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)

• 7.5 Online pharmacy - Market size and forecast 2022-2027 
• Exhibit 60: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 61: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ billion)
• Exhibit 62: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Distribution Channel 
• Exhibit 64: Market opportunity by Distribution Channel ($ billion)
• Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 67: Chart on Market share by geography 2022-2027 (%)
• Exhibit 68: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 69: Chart on Geographic comparison
• Exhibit 70: Data Table on Geographic comparison

• 9.3 Asia - Market size and forecast 2022-2027 
• Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.4 North America - Market size and forecast 2022-2027 
• Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.5 Europe - Market size and forecast 2022-2027 
• Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027 
• Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 China - Market size and forecast 2022-2027 
• Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.9 India - Market size and forecast 2022-2027 
• Exhibit 95: Chart on India - Market size and forecast 2022-2027 ($ billion)
• Exhibit 96: Data Table on India - Market size and forecast 2022-2027 ($ billion)
• Exhibit 97: Chart on India - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on India - Year-over-year growth 2022-2027 (%)

• 9.10 Russia - Market size and forecast 2022-2027 
• Exhibit 99: Chart on Russia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 100: Data Table on Russia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 101: Chart on Russia - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on Russia - Year-over-year growth 2022-2027 (%)

• 9.11 Mexico - Market size and forecast 2022-2027 
• Exhibit 103: Chart on Mexico - Market size and forecast 2022-2027 ($ billion)
• Exhibit 104: Data Table on Mexico - Market size and forecast 2022-2027 ($ billion)
• Exhibit 105: Chart on Mexico - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on Mexico - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 107: Market opportunity by geography ($ billion)
• Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 109: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 111: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 112: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 113: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 114: Matrix on vendor position and classification

• 12.3 Abbott Laboratories
• Exhibit 115: Abbott Laboratories - Overview
• Exhibit 116: Abbott Laboratories - Business segments
• Exhibit 117: Abbott Laboratories - Key offerings
• Exhibit 118: Abbott Laboratories - Segment focus

• 12.4 Astellas Pharma Inc.
• Exhibit 119: Astellas Pharma Inc. - Overview
• Exhibit 120: Astellas Pharma Inc. - Product / Service
• Exhibit 121: Astellas Pharma Inc. - Key news
• Exhibit 122: Astellas Pharma Inc. - Key offerings

• 12.5 AstraZeneca Plc
• Exhibit 123: AstraZeneca Plc - Overview
• Exhibit 124: AstraZeneca Plc - Product / Service
• Exhibit 125: AstraZeneca Plc - Key news
• Exhibit 126: AstraZeneca Plc - Key offerings

• 12.6 Aurobindo Pharma Ltd. 
• Exhibit 127: Aurobindo Pharma Ltd. - Overview
• Exhibit 128: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 129: Aurobindo Pharma Ltd. - Key offerings

• 12.7 Bayer AG
• Exhibit 130: Bayer AG - Overview
• Exhibit 131: Bayer AG - Business segments
• Exhibit 132: Bayer AG - Key news
• Exhibit 133: Bayer AG - Key offerings
• Exhibit 134: Bayer AG - Segment focus

• 12.8 Boehringer Ingelheim International GmbH 
• Exhibit 135: Boehringer Ingelheim International GmbH - Overview
• Exhibit 136: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 137: Boehringer Ingelheim International GmbH - Key news
• Exhibit 138: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 139: Boehringer Ingelheim International GmbH - Segment focus

• 12.9 Bristol Myers Squibb Co. 
• Exhibit 140: Bristol Myers Squibb Co. - Overview
• Exhibit 141: Bristol Myers Squibb Co. - Product / Service
• Exhibit 142: Bristol Myers Squibb Co. - Key news
• Exhibit 143: Bristol Myers Squibb Co. - Key offerings

• 12.10 Daiichi Sankyo Co. Ltd. 
• Exhibit 144: Daiichi Sankyo Co. Ltd. - Overview
• Exhibit 145: Daiichi Sankyo Co. Ltd. - Business segments
• Exhibit 146: Daiichi Sankyo Co. Ltd. - Key news
• Exhibit 147: Daiichi Sankyo Co. Ltd. - Key offerings
• Exhibit 148: Daiichi Sankyo Co. Ltd. - Segment focus

• 12.11 Dr Reddys Laboratories Ltd. 
• Exhibit 149: Dr Reddys Laboratories Ltd. - Overview
• Exhibit 150: Dr Reddys Laboratories Ltd. - Business segments
• Exhibit 151: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibit 152: Dr Reddys Laboratories Ltd. - Segment focus

• 12.12 Eli Lilly and Co.
• Exhibit 153: Eli Lilly and Co. - Overview
• Exhibit 154: Eli Lilly and Co. - Product / Service
• Exhibit 155: Eli Lilly and Co. - Key offerings

• 12.13 GlaxoSmithKline Plc
• Exhibit 156: GlaxoSmithKline Plc - Overview
• Exhibit 157: GlaxoSmithKline Plc - Business segments
• Exhibit 158: GlaxoSmithKline Plc - Key news
• Exhibit 159: GlaxoSmithKline Plc - Key offerings
• Exhibit 160: GlaxoSmithKline Plc - Segment focus

• 12.14 Johnson and Johnson Services Inc. 
• Exhibit 161: Johnson and Johnson Services Inc. - Overview
• Exhibit 162: Johnson and Johnson Services Inc. - Business segments
• Exhibit 163: Johnson and Johnson Services Inc. - Key news
• Exhibit 164: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 165: Johnson and Johnson Services Inc. - Segment focus

• 12.15 Merck and Co. Inc.
• Exhibit 166: Merck and Co. Inc. - Overview
• Exhibit 167: Merck and Co. Inc. - Business segments
• Exhibit 168: Merck and Co. Inc. - Key news
• Exhibit 169: Merck and Co. Inc. - Key offerings
• Exhibit 170: Merck and Co. Inc. - Segment focus

• 12.16 Pfizer Inc.
• Exhibit 171: Pfizer Inc. - Overview
• Exhibit 172: Pfizer Inc. - Product / Service
• Exhibit 173: Pfizer Inc. - Key news
• Exhibit 174: Pfizer Inc. - Key offerings

• 12.17 Viatris Inc.
• Exhibit 175: Viatris Inc. - Overview
• Exhibit 176: Viatris Inc. - Business segments
• Exhibit 177: Viatris Inc. - Key offerings
• Exhibit 178: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 179: Inclusions checklist
• Exhibit 180: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 181: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 182: Research methodology
• Exhibit 183: Validation techniques employed for market sizing
• Exhibit 184: Information sources

• 13.5 List of abbreviations 
• Exhibit 185: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio